Loading...
Loading...
Browse all stories on DeepNewz
VisitWhat will be the primary benefit reported from the BiVACOR titanium heart implantation by the end of 2024?
Increased patient survival rate • 25%
Improved quality of life • 25%
Reduced need for medication • 25%
Other • 25%
Medical reports, news articles, BiVACOR press releases
Doctors Successfully Implant BiVACOR Titanium Heart Using Maglev Technology in 58-Year-Old Man
Aug 3, 2024, 10:56 AM
In a groundbreaking medical achievement, doctors in the United States have successfully implanted a fully mechanical titanium heart in a 58-year-old man. The heart, developed by BiVACOR, utilizes Maglev technology, which is also used in high-speed rail travel, to function effectively. This world-first implantation has kept the patient alive for days, marking a significant milestone in medical science. Experts believe the impact of this innovation will be tremendous, potentially revolutionizing the future of heart transplants and artificial organs.
View original story
Infection • 25%
Device malfunction • 25%
Rejection • 25%
No major complications • 25%
1 • 25%
2-3 • 25%
4-5 • 25%
More than 5 • 25%
Yes • 50%
No • 50%
Reduced surgery count • 25%
Faster recovery times • 25%
Lower complication rates • 25%
Cost savings • 25%
Yes • 50%
No • 50%
Faster recovery time • 25%
Reduced pain • 25%
Shorter hospital stay • 25%
Improved surgical precision • 25%
Cleveland Clinic • 25%
Mayo Clinic • 25%
Johns Hopkins Hospital • 25%
Other • 25%
Reduced recovery time • 25%
Increased precision • 25%
Lower complication rates • 25%
Other • 25%
Yes • 50%
No • 50%
Successful with no complications • 25%
Successful with minor complications • 25%
Successful with major complications • 25%
Unsuccessful • 25%
Increased surgical precision • 25%
Reduced surgery time • 25%
Improved patient outcomes • 25%
Enhanced training for surgeons • 25%
Increased survival rate • 25%
Reduced secondary cancer rate • 25%
Improved quality of life • 25%
Other • 25%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
Other • 25%
Mechanical failure • 25%
Patient immune response • 25%
Surgical complications • 25%